In the month, where the rupee plunged to deepest of its lows, the pharmaceutical market has also had the growth shocker with the markets growing at 1.1 per cent, which is the lowest in years of the market existence. The last low growth experienced in the market was in November 2012 with that month registering 4.3 per cent. The anti-diabetic market grew a slight better than the previous month due to the lifting of ban on the pioglitazone and its combinations.
The Indian Pharma Market (IPM) is valued at Rs 6357 crores in August 2013. It has grown at 1.1 per cent in August 2013. For the month of August 2013, amongst the top 10, Sun Pharma has registered a growth of 14.9 per cent, Alkem at 5.9 per cent and Cipla at 4.9 per cent. 30 corporates have crossed the growth of IPM for the month of August 2013 amongst top 50. Amongst the top 50 corporates, Biocon has the highest growth of 34 per cent followed by Akumentis at 28.9 per cent and Glenmark at 21.8 per cent. Amongst the 11-20 ranked companies, Glenmark has shown high growth at 21.8 per cent followed by Emcure at 8.8 per cent and USV at seven per cent
| With Bonus Units at Full Value | ||||||||
| Val in Crs | Rank | MAT Aug -13 | Aug-13 | |||||
| CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 72500 | 100.00 | 8.2 | 6357 | 100.00 | 1.1 | ||
| Abbott + Abbott HC + Novo | 1 | 1 | 4908 | 6.77 | 5.1 | 411 | 6.46 | -4.6 |
| Sun Pharma | 2 | 2 | 3728 | 5.14 | 18.1 | 329 | 5.18 | 14.9 |
| Cipla | 3 | 3 | 3666 | 5.06 | 7.0 | 312 | 4.91 | 4.9 |
| Zydus + Biochem | 4 | 4 | 3241 | 4.47 | 17.7 | 289 | 4.55 | 3.8 |
| Glaxo | 5 | 6 | 3114 | 4.30 | -1.2 | 248 | 3.90 | -17.6 |
| Ranbaxy | 6 | 5 | 2991 | 4.13 | 6.2 | 253 | 3.97 | 0.1 |
| Mankind | 7 | 8 | 2640 | 3.64 | 14.8 | 233 | 3.66 | -3.0 |
| Alkem + Cachet + Indchemie | 8 | 7 | 2541 | 3.50 | 12.4 | 237 | 3.72 | 5.9 |
| Pfizer + Wyeth | 9 | 10 | 2184 | 3.01 | 2.3 | 184 | 2.90 | -8.1 |
| Lupin | 10 | 9 | 2183 | 3.01 | 9.0 | 188 | 2.95 | 0.1 |
| Macleods | 11 | 11 | 1879 | 2.59 | 13.1 | 167 | 2.63 | 2.0 |
| Intas | 12 | 14 | 1807 | 2.49 | 13.9 | 155 | 2.44 | 6.4 |
| Emcure + Zuventus | 13 | 12 | 1748 | 2.41 | 12.3 | 165 | 2.60 | 8.8 |
| Aristo | 14 | 13 | 1712 | 2.36 | 11.1 | 163 | 2.56 | 5.4 |
| Dr. Reddys | 15 | 16 | 1600 | 2.21 | 10.1 | 137 | 2.15 | 2.0 |
| Sanofi-Aventis + Universal | 16 | 17 | 1548 | 2.14 | 4.2 | 131 | 2.07 | -1.1 |
| Glenmark | 17 | 15 | 1480 | 2.04 | 15.0 | 146 | 2.30 | 21.8 |
| USV | 18 | 18 | 1317 | 1.82 | 16.4 | 115 | 1.81 | 7.0 |
| Micro + Bal | 19 | 19 | 1307 | 1.80 | 2.4 | 114 | 1.79 | -0.2 |
Amongst upcoming corporates, Corona Remedies has grown at 73.1 per cent, Akumentis at 28.9 per cent and Eris at 21.1 per cent. Khandelwal Labs and Comed have crossed the Rs 50-crore mark in the IPM.
The DPCO 2013 containing molecules market was at -12.3 per cent whereas the non-DPCO market grew by 3.3 per cent resulting in an overall growth of 1.1 per cent for August 2013. The DPCO 2013 portfolio for GSK degrew at 30.4 per cent and Ranbaxy degrew by 21.1, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio degrowing at 1.7.
Val in Crs | With Bonus in Crs | |||
Super Group | MAT Aug 13 | GR% | Mth Aug 13 | GR% |
| IPM | 72500 | 8.2 | 6357 | 1.1 |
| ANTI-INFECTIVES | 12829 | 7.9 | 1154 | -1.1 |
| CARDIAC | 8803 | 9.6 | 746 | 4.0 |
| GASTRO INTESTINAL | 8188 | 7.3 | 729 | -3.8 |
| VITAMINS / MINERALS / NUTRIENTS | 6350 | 6.7 | 560 | -0.9 |
| RESPIRATORY | 5631 | 9.8 | 484 | 6.2 |
| PAIN / ANALGESICS | 5287 | 5.6 | 458 | -3.3 |
| ANTI DIABETIC | 4915 | 11.3 | 428 | 6.4 |
| GYNAECOLOGICAL | 4648 | 5.2 | 389 | -0.4 |
| NEURO / CNS | 4454 | 9.6 | 382 | 4.7 |
| DERMA | 3826 | 8.3 | 351 | 5.9 |
| OPHTHAL / OTOLOGICALS | 1294 | 7.9 | 115 | 5.5 |
| HORMONES | 1250 | 11.7 | 103 | -3.8 |
| OTHERS | 982 | 9.0 | 95 | 13.8 |
| ANTI-NEOPLASTICS | 956 | 22.4 | 88 | 19.3 |
| BLOOD RELATED | 868 | 2.7 | 75 | 0.3 |
| VACCINES | 854 | 0.0 | 69 | -10.9 |
| ANTI MALARIALS | 620 | 5.4 | 68 | -12.1 |
| SEX STIMULANTS / REJUVENATORS | 423 | 12.7 | 33 | 4.1 |
| STOMATOLOGICALS | 322 | 7.6 | 28 | 2.8 |
Amongst the various molecules with specific strengths under DPCO 2013, Amoxycillin – Clavulanic acid degrew at 4.2 per cent, Atorvastatin market degrew by 27.8 per cent, Paracetamol degrew by 20.1 per cent and Azithromycin degrew by 18.7 per cent. Not only value, the market has witnessed a negative growths in the units as well in both the categories.
From therapy perspective 10 therapies have outgrown the IPM growth. The anti-infective market has a degrowth of 1.1 per cent whereas respiratory market is at 6.2 per cent growth. The anti-diabetic market has grown at 6.4 per cent and cardiac at four per cent in chronic business.
From regional perspective, 13 regions have outgrown the IPM growth. Rajasthan has grown the highest at 11 per cent whereas Mumbai have registered low growth in August 2013. Eight regions have had negative growths in August 13.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage
For more information, visit http://www.aiocd.net
- Advertisement -